Evidence map›Paper›PMID 42053806›Full record

ArticleAnnals of hematology2026

Combined blinatumomab and CD19 CAR T-cell therapy for newly diagnosed adult Ph⁻ BCP-ALL: A retrospective study.

Boxuan Jiang, Yiyan Zhu, Yucheng Jiang, Jiayi Huang, Yizi Liu, Meng Tang, Jing Lu, Suning Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Boxuan Jiang *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, , Jiangsu Province, China.
Yiyan Zhu *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, , Jiangsu Province, China.
Yucheng Jiang *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, , Jiangsu Province, China.
Jiayi HuangNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, , Jiangsu Province, China.
Yizi LiuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, , Jiangsu Province, China.
Meng TangNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, , Jiangsu Province, China.
Jing LuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, , Jiangsu Province, China. lujing@suda.edu.cn.
Suning ChenNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, , Jiangsu Province, China. chensuning@suda.edu.cn.

Funding

National Key Research and Development Program of China 2019YFA0111000, 2022YFC2502700National Natural Science Foundation of China 82470166, 82200149, 82170158, 82100175, 82100170Natural Science Foundation of Jiangsu Province BK20231195, BK20210087Open Project of Jiangsu Biobank of Clinical Resources SBK202003001, SBK202003003Suzhou Science and Technology Program SYW2025092
6 · The paper itself

Abstract

This retrospective study evaluated the efficacy and safety of integrating blinatumomab and CD19 CAR T-cell therapy into frontline treatment for newly diagnosed adult Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. All patients received Hyper-CVAD-based consolidation with integrated immunotherapy. Forty patients were classified according to frontline immunotherapy strategy: single-modality therapy (BiTE/CART group, n = 22) or combined use of both modalities (BiTE + CART group, n = 18). After a median follow-up of 23.8 months, the BiTE + CART group demonstrated significantly improved overall survival and relapse-free survival compared with the BiTE/CART group (2-year overall survival: 100% vs. 58.4%; 2-year relapse-free survival: 94.4% vs. 53.1%). A higher cumulative exposure to immunotherapy (≥ 4 cycles) was associated with improved outcomes. Notably, survival in non-transplanted patients was comparable to those undergoing allogeneic transplantation in first remission. These findings support the integration of blinatumomab and CD19 CAR T-cell therapy as a promising strategy to improve disease control in Ph⁻ B-cell precursor acute lymphoblastic leukemia, pending validation in prospective studies.

Indexed as

Antibodies, BispecificAntigens, CD19Immunotherapy, AdoptivePrecursor B-Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDisease-Free SurvivalFemaleHumansMaleMiddle AgedPhiladelphia ChromosomeAntibodies, BispecificAntigens, CD19blinatumomabCD19 molecule, humanCyclophosphamideReceptors, Chimeric AntigenVincristineBlinatumomabCD19 CAR T-cell therapyImmunotherapy integrationPhiladelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia

Identifiers

PMID42053806
PMCPMC13128765

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.